The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen

Current Medical Research and Opinion

Volumn 29, Issue 11, 2013, Pages 1527-1532

  Mercadante, Sebastiano ^a   Prestia, Giovanna ^a   Casuccio, Alessandra ^b  

^a LA MADDALENA CANCER CENTER   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

Breakthrough episodic pain; Cancer pain; Opioids; Sublingual tablet

Indexed keywords

FENTANYL; MORPHINE;

ADULT; AGED; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; BREAKTHROUGH PAIN; BREAST CANCER; CANCER PATIENT; COLON CANCER; DISEASE SEVERITY; DROWSINESS; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PALLIATIVE THERAPY; PANCREAS CANCER;

ADMINISTRATION, SUBLINGUAL; AGED; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PALLIATIVE CARE; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84885795229     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.826640     Document Type: Article

References (30)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;41:273-81 (Pubitemid 20187930)
2. Davies A, Zeppetella G, Andersen S, et al. Multicentre European study of breakthrough cancer pain: characteristics and patient perceptions of current and potential management strategies. Eur J Pain 2011;15:756-63
3. Mercadante S, Valle A, Porzio G, et al. Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiological and clinical studies. Curr Med Res Opin 2013;29:667-71
4. Portenoy RK, Payne D, Jacobson P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81:129-34 (Pubitemid 29199908)
5. Hanks GW, De Conno F, Cherny N, et al. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93 (Pubitemid 32238990)
6. Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs 2012;72:181-90
7. Davies A, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Association of Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009;13:331-8
8. Zeppetella G, Messina J, Xie F, et al. Consistent and clinically relevant effects with fentanyl buccal tablet in the treatment of patients receiving maintenance opioid therapy and experiencing cancer-related breakthrough pain. Pain Pract 2010;10:287-93
9. Kleeberg UR, Filbet M, Zeppetella G. Fentanyl buccal tablet for breakthrough cancer pain: why titrate? Pain Pract 2011;11:185-90
10. Mercadante S. Breakthrough pain: on the road again. Eur J Pain 2009;13:329-30
11. Mercadante S. Rapid onset opioids for breakthrough pain: titrating or not titration or not titrating, this is the question. Eur J Pain 2011;5(Suppl):443-8
12. Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol Hematol 2011;80:460-5
13. Davies A, Vriens J, Kennett A, et al. An observational study of oncology patients' utilization of breakthrough pain medication. J Pain Symptom Manage 2008;35:406-11
14. Mercadante S, Villari P, Ferrera P, et al. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004;27: 352-9 (Pubitemid 38410903)
15. Mercadante S, Intravaia G, Villari P, et al. Intravenous morphine for episodicbreakthrough pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage 2008;35:307-13
16. Mercadante S, Villari P, Ferrera P, et al. The use of opioids for breakthrough pain in an acute palliative care unit by using doses proportional to opioid basal regimen. Clin J Pain 2010;26:306-9
17. Mercadante S, Ferrera P, Adile C, et al. The use of fentanyl buccal tablets in doses proportional to the doses of opioids used for background analgesia for the treatment of breakthrough cancer pain in highly tolerant cancer patients. J Pain Symptom Manage 2011;42:464-9
18. Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Cancer 2007;96:1828-33 (Pubitemid 46912022)
19. Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin 2013;29:93-7
20. Chwieduk C, McKeage K. Fentanyl sublingual in breakthrough pain in opioidtolerant adults with cancer. Drugs 2010;70:2281-8
21. Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2004;52:249-53 (Pubitemid 40208864)
22. Lennernas B, Frank-Lissbrant I, Lennernas H, et al. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study. Palliat Med 2010;24:286-93
23. Rauck R, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentany lorally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin 2009;25:2877-85
24. The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Support Care Cancer 2013;21:2335-9
25. Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008;35:563-7
26. Aronoff G, Brennan M, Pritchard D, et al. Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Med 2005;6:305-14 (Pubitemid 41725955)
27. Viganò A, Bruera E, Suarez-Almazor M. Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer 1998;83:1244-50 (Pubitemid 28419080)
28. Mercadante S, Casuccio A, Pumo S, et al. Factors influencing the opioid response in advanced cancer patients with pain followed at home. The effects of age and gender. Support Care Cancer 2000;8:123-30 (Pubitemid 30114820)
29. Farrar J, Polomano R, Berlin J, et al. A comparison of change in the 0-10 numeric rating scale to a pain relief scale and global medication performance scale in a short-term clinical trial of breakthrough pain intensity. Anesthesiology 2010;11:1464-72
30. Mercadante S, Adile A, Torta R, et al. Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. Curr Med Res Opin 2013;29:93-7